<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941496</url>
  </required_header>
  <id_info>
    <org_study_id>H-45051</org_study_id>
    <nct_id>NCT03941496</nct_id>
  </id_info>
  <brief_title>Azacytidine During Anti-tuberculosis Therapy</brief_title>
  <acronym>AZA</acronym>
  <official_title>Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Dinardo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis has been shown to make immune genes inaccessible and slows immune response The
      purpose of this research is to see if if azacitidine is safe and can return the ability of
      the body to resist tuberculosis (TB), a contagious infection that attacks the lungs.
      Individuals with tuberculosis are being asked to participate. Some will receive a drug to
      restore a host immunity while others can choose to receive standard of care. All patients
      will continue to receive standard of care tuberculosis therapy regardless of whether they
      chose to participate in the study.

      This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of
      oral azacitidine in pulmonary TB patients during the continuation phase of ATT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All study participants will have drug-sensitive TB and successfully complete 2 months of
      standard intensive phase 4-drug RHZE (rifampin, isoniazid, pyrazinamide, ethambutol). By
      definition, to have uncomplicated TB, participants will have become asymptomatic and
      smear-negative by the end of intense phase anti-Tb therapy and be ready to transition from
      standard 4-drug (INH, RIF, ETH, PZA) intense phase to the 2-drug continuation phase (INH and
      RIF). All participants will have 1 and 2-month cultures &quot;no growth to date&quot; at the time of
      AZA administration (1-month cultures will therefore be no growth at ~6 weeks and 2-month
      cultures will be no growth at ~2 weeks).

      Eligible study participants will be allocated to the AZA in sequential blocks of 6 study
      participants.

      The following will be performed during screening and work up. These procedures will be
      performed within 4 weeks prior to administration of study drug. A signed and dated IRB
      approved consent form will be obtained before study specific procedures are performed.
      Procedures part of routine care are not considered study specific. All subjects will be
      screened for eligibility before enrollment.

        1. Informed consent

        2. Full History and Exam

             1. Concomitant medications

             2. Allergies

             3. Alcohol and substance use

             4. Vital signs and physical exam

        3. Review of baseline laboratory results including CBC, liver function, renal function and
           microbiology studies

           a. After consent, CBC, coagulation and Renal and liver function studies will occur
           within 14-days prior to study drug.

           i. CBC: WBC, Hemoglobin, Hematocrit, Platelet count ii. Coagulation studies: PT and PTT
           iii. Sodium, potassium, blood urea nitrogen, creatinine, glucose, AST, ALT, alkaline
           phosphatase, total bilirubin b. After screening labs, participants with cytopenias or
           inappropriate coagulation, renal or liver function (see inclusion and exclusion
           criteria), will not receive study drug

        4. Pregnancy test (within 24 hours prior to AZA dosing)

      PHASE IB: AZACITIDINE AFTER 10 WEEKS OF ATT; PRE-TREATMENT EVALUATION

      1-Month pre-study drug: Recruitment, consent and completion of the Case Report Form (CRF)
      including baseline history and physical exam will occur between week 4-10 of Anti-TB therapy.

      0-2 weeks pre-study drug: Blood draw for baseline immune correlates and to screen for
      eligibility criteria (CBC, CMP and coagulation) will occur 1-14 days prior to azacitidine
      dosing. A pregnancy test will occur within 24 hours prior to AZA dosing. (A CMP will include
      measurement of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase,
      total bilirubin, creatinine, chloride, carbon dioxide/bicarbonate, sodium, potassium and
      glucose. A CBC will include a differential and includes red blood cell count, white blood
      cell count, hemoglobin, hematocrit, platelet count, percent and absolute neutrophil count,
      percent and absolute lymphocyte count, percent and absolute monocyte count, and percent and
      absolute eosinophil count.)

      CYCLE 1 DAYS 1-21 Oral AZA dosing will occur during weeks 10-13 of ATT (+/- 1 week).
      Pretreatment enrollment labs will be reviewed, and a symptom screen and a focused exam will
      occur before dispensing the oral AZA. A weekly telephone call will screen for symptoms with
      clinically relevant symptoms triggering a clinical visit and in-person evaluation.

      POST DOSE FOLLOW UP Additional screenings for cytopenias, renal and liver function will occur
      weekly (between days 4-9, 11-16 and 18-23, and 25-30). Two mL of plasma will be collected at
      the same time for pharmacokinetic analysis (between days 4-9, 11-16 and 18-23, and 25-30).
      Follow up study visits and clinical evaluation will occur monthly for the last 4 months of
      anti-TB therapy as standard of care. Additional blood draws for PBMCs, and immune correlates
      will occur at week 16 of ATT (week 6 post commencing AZA).

      PHASE II: AZACITIDINE AFTER 10 WEEKS OF ATT; PRE-TREATMENT EVALUATION

      1-Month pre-study drug: Recruitment, consent and completion of the Case Report Form (CRF)
      including baseline history and physical exam will occur between week 4-10 of Anti-TB therapy.

      0-2 weeks pre-study drug: Blood draw for baseline immune correlates and to screen for
      eligibility criteria (CBC, CMP and coagulation) will occur within 1-14 days prior to
      azacitidine dosing. A pregnancy test will occur within 24 hours prior to AZA dosing.

      CYCLE 1 DAYS 1-21 AZA dosing will occur during weeks 10-13 of ATT (+/- 1 week). Pretreatment
      enrollment labs will be reviewed, and a symptom screen and a focused exam will occur before
      dispensing the oral AZA. A weekly telephone call will screen for symptoms with clinically
      relevant symptoms triggering a clinical visit and in-person evaluation.

      POST DOSE FOLLOW UP Additional screenings for cytopenias, renal and liver function will occur
      weekly (between days 4-9, 11-16 and 18-23). Follow up study visits and clinical evaluation
      will occur at week 12 (at the peak of AZA induced toxicity), 16, 20 and 24. Additional blood
      draws for PBMCs and immune correlates will occur at week 16 of ATT (week 6 post commencing
      AZA).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of using azacitidine in pulmonary TB patients during the continuation phase of ATT.
The study design evaluates the safety of AZA after 10 weeks of Anti-Tuberculosis Therapy. In the Phase Ib dose escalation stage, 6 participants will receive oral AZA at 100mg PO once a day. After each phase, participants will be monitored for adverse effects and preliminary DNA methylation and immune analysis will be performed to evaluate if the dose should be escalated or the study should proceed to the Phase IIa stage (after FDA/IRB approval of Phase Ib results).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall incidence of all IP-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>using Common Toxicity Criteria v 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall severity of all IP-related adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>using Common Toxicity Criteria v 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of epigenetic-mediated immune exhaustion</measure>
    <time_frame>baseline and Week 16</time_frame>
    <description>measured by using 1) a standardized mycobacterial growth inhibition assay (MGIA) that measures ex vivo mycobacterial killing; 2) 18-parameter flow cytometry based multi-dimensional immune profiling (MDIP); and 3) epigenetic assays</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>AZA Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase Ib dose escalation stage, 6 participants will receive oral AZA at 100mg PO once a day. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 18 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.
Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:
100 mg PO once daily x 14 days for 6 individuals
100 mg PO twice daily x 14 days for 6 individuals
150 mg PO twice daily x 14 days for 6 individuals
200 mg PO twice daily x 14 days for 6 individuals
200 mg PO twice daily x 21 days for 6 individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>18 controls will not receive study drug and choose to receive standard of care. All participants receive standard of care antibiotics against tuberculosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine Injection Group</intervention_name>
    <description>In Phase Ib dose escalation stage, 6 participants will receive oral AZA at 100mg PO once a day. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 18 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:
a 5% decrease DNA methylation levels in at least 25% of genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy
a 25% effect size increase in TNF and IFN-Î³ signaling pathways
a 25% effect size increase in ex vivo mycobacterial growth inhibition assay</description>
    <arm_group_label>AZA Treatment</arm_group_label>
    <other_name>AZA Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Microbiologically confirmed pulmonary Tuberculosis, including cavitary, lymph node or
             military pulmonary TB

          3. Asymptomatic by the end of intense phase ATT (8 weeks) and remains asymptomatic until
             AZA dosing.

          4. AFB-smear negative at the end of intensive phase.

          5. 1-month sputum culture negative and 2-month sputum with no growth when the AZA is
             administered.

          6. HIV-negative.

          7. Adequate hepatic function (direct bilirubin 1.5 x upper limit of normal (ULN) or less,
             ALT and/or AST 1.5 x ULN or less) at the end of ATT intensive phase.

          8. Adequate renal function (creatinine 2 mg/dl or less).

          9. Written informed consent obtained

         10. Women and men of childbearing potential must agree to use 2 clinically effective
             methods of contraception (e.g., oral, intrauterine device [IUD], diaphragm plus
             spermicide, injectable, transdermal or implantable contraception) during the study and
             at least 3 months after the last treatment.

        Exclusion Criteria:

          1. HIV-infection

          2. Pre-existing liver disease

          3. Smear-positive at 2 months

          4. 1-month or 2 month sputum culture positive at the time of AZA administration.

          5. Participants with extrapulmonary TB.

          6. History or current drug-resistant tuberculosis

          7. After consent and within two weeks before Investigational Product (IP), a study CBC
             will be performed and individuals with cytopenias (Hemoglobin &lt;12 g/dL, WBC &lt; 3 cells/
             mm3, ANC &lt; 2,000 cells/mm3, or platelets &lt; 110 platelets/mm3) will be excluded.

          8. Any concurrent uncontrolled medical condition, laboratory abnormality, or psychiatric
             illness which could place the patient at unacceptable risk of study treatment.

          9. Pregnant or breast feeding females.

         10. Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing
             signs/symptoms related the infection without improvement despite appropriate
             antibiotics, antiviral therapy and/or other treatment)

         11. History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis),
             celiac disease (ie. sprue), prior gastrectomy or upper bowel removal, or any other
             gastrointestinal disorder or defect that would interfere with the absorption,
             distribution, metabolism or excretion of the study drug and/or predispose the subject
             to an increased risk of gastrointestinal toxicity

         12. Cancer or hematologic malignancy currently active or active in the past three years.

         13. Abnormal coagulation parameters (PT &gt;15 seconds, PTT &gt;40 seconds, and/or INR &gt;1.5)

         14. Significant active cardiac disease within the previous 6 months including:

               1. NYHA class 4 CHF

               2. Unstable angina

               3. Myocardial infarction

        13. Active viral infection with HIV or hepatitis type B or C

        14. Known or suspected hypersensitivity to azacytidine or mannitol

        15. Inability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew DiNardo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew DiNardo</last_name>
    <phone>832.822-1331</phone>
    <email>dinardo@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harris Health System - Ben Taub Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew DiNardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elizabeth Guy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Chiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian Coarfa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimal Rajapakshe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Andrew Dinardo</investigator_full_name>
    <investigator_title>Principal Investigator / Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>Mycobacterium tuberculosis</keyword>
  <keyword>Mtb</keyword>
  <keyword>anti-TB therapy</keyword>
  <keyword>ATT</keyword>
  <keyword>rifampin (R), isoniazid (H) pyrazinamide (Z) ethambutol (E)</keyword>
  <keyword>RHZE</keyword>
  <keyword>rifampin (R), isoniazid (H)</keyword>
  <keyword>RH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

